Conversely, MAPK pathway reactivation drives selpercatinib resistance either by (1) secondary RET solvent front mutations or MET amplifications, or (2) selection for RET-wild-type tumor cell populations characterized by an alternative driver. Here, RET is linked to neoplasm.